Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.82 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | PARG | Q86W56 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237511 | 0.92 | MMP13 (0.69) | MMP13SLC22A8TP53HDAC1HDAC8 | |
| SCHEMBL6244295 | 0.91 | MMP13 (1.00) | MMP13SLC22A8HDAC1HDAC8HDAC6 | |
| SCHEMBL6396382 | 0.89 | MMP13 (0.85) | MMP13SLC22A8HDAC1HDAC8HDAC6 | |
| SCHEMBL6397427 | 0.88 | MMP13 (0.91) | MMP13SLC22A8HDAC1PARGSMN1; SMN2 | |
| SCHEMBL6390295 | 0.88 | MMP13 (0.63) | MMP13SLC22A8PARGSMN1; SMN2L3MBTL1 | |
| SCHEMBL6390034 | 0.87 | MMP13 (0.73) | MMP13SLC22A8TP53HDAC1DPP4 | |
| SCHEMBL6217699 | 0.86 | MMP13 (0.61) | MMP13SLC22A8HDAC1HDAC8HDAC6 | |
| SCHEMBL6256616 | 0.86 | MMP13 (0.59) | MMP13SLC22A8TP53HDAC1HDAC8 | |
| SCHEMBL6390042 | 0.85 | MMP13 (0.82) | MMP13SLC22A8TP53HDAC1PARG | |
| SCHEMBL6390967 | 0.84 | MMP13 (0.87) | MMP13SLC22A8HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962922-B2 | Alkynylated quinazoline compounds | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-08 | — | — | US | claimed |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD | 2005-11-03 | — | — | US | claimed |
| EP-1534274-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-06-01 | — | — | EP | claimed |
| EP-1525030-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-04-27 | — | — | EP | claimed |
| US-20040023969-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-05 | — | — | US | claimed |
| US-20040019055-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | claimed |
| WO-2004006914-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004007025-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | claimed |
| WO-2003033477-A1 | ALKYNLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | claimed |
| US-6962922-B2 | Alkynylated quinazoline compounds | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD | 2005-11-03 | — | — | US | disclosed |
| EP-1361873-A4 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1534274-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | disclosed |
| WO-2003033477-A1 | ALKYNLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033478-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019055-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885SLC22A8 155/4885TP53 3464/4885 |
| US-20040023969-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885SLC22A8 299/4885TP53 2454/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | MMP13 1/4885SLC22A8 1442/4885TP53 3418/4885 |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | MMP13 1/4885SLC22A8 811/4885TP53 3387/4885 |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | MMP13 1/4885SLC22A8 827/4885TP53 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.